MarginScan™
for Skin Cancer
Non-melanoma skin cancers are the most common cancers worldwide, yet current surgical approaches force tradeoffs between speed, cost, and tissue preservation.
MarginScan™ enables Mohs-like margin control without intraoperative histology. Dermatologists can excise conservatively and confirm clear margins through an electrical assessment of the Cole relaxation frequency—without an onsite lab.
Compared to traditional Mohs surgery, MarginScan offers:
- Faster, more predictable procedures
- Reduced cost and resource intensity
- Improved cosmetic outcomes
- Lower recurrence risk compared to simple excision
- Mohs-level outcomes, without Mohs-level complexity.
Commercial Status: A letter of intent for exclusive U.S. distribution has been signed with Epredia, PHC Holdings' cancer diagnostics division. A 2027 launch is anticipated.